|Articles|January 11, 2023
- Pharmaceutical Executive: January 2023
- Volume 43
- Issue 01
Pharmaceutical Executive, January 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive January 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 3 years ago
Key Factors Attributing to a Successful Product Launchalmost 3 years ago
Closing the Digital Gap: FDA’s Oversight of Social Mediaalmost 3 years ago
Sales-Rep Compensation: Adding Long-Term Incentives to Mixalmost 3 years ago
Co-creating New Innovationsalmost 3 years ago
The Potential Impact of the IRAalmost 3 years ago
Patient Hubs Continue Growthalmost 3 years ago
Social Media’s Complex Climbalmost 3 years ago
Industry Workforce Seeks Clarityalmost 3 years ago
Cybersecurity Threats & PharmaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
